ACE2 Peptide Fragment Interaction with Different S1 Protein Sites

Kuznetsov, Aleksei; Arukuusk, Piret; Härk, Heleri Heike; Juronen, Erkki; Ustav, Mart; Langel, Ülo; Järv, Jaak

doi:10.1007/s10989-021-10324-7

Cited by 7 publications

(7 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several studies introduced peptide inhibitors against RBD. However, they used different approaches to design peptides [ [54] , [55] , [56] , [57] , [58] , [59] , [60] ], and therefore, their results may seem incomparable to the present study. In the next step, 11 peptides having the greatest OSPREY scores were chosen and their probable allergenicity and toxicity were evaluated.…”

Section: Resultsmentioning

confidence: 67%

Inhibition of SARS-CoV-2 pathogenesis by potent peptides designed by the mutation of ACE2 binding region

Pourmand

Zareei

Shahlaei

et al. 2022

Computers in Biology and Medicine

View full text Add to dashboard Cite

Section: Resultsmentioning

confidence: 67%

Inhibition of SARS-CoV-2 pathogenesis by potent peptides designed by the mutation of ACE2 binding region

Pourmand

Zareei

Shahlaei

et al. 2022

Computers in Biology and Medicine

View full text Add to dashboard Cite

“…The original Wuhan strain rapidly evolved into different variants, including Alpha (B.1.1.7 and Q lineages), Beta (B.1.351 and descendent lineages), Gamma (P.1 and descendent lineages), Delta (B.1.617.2 and AY lineages), Epsilon (B.1.427 and B.1.429), Eta (B.1.525), Iota (B.1.526), Kappa (B.1.617.1), Mu (B.1.621 and B.1.621.1), Zeta (P.2), 1.617.3, and Omicron (strain B.1.1.529) ( 7 – 9 ). The Omicron variant of 2019-nCoV was first detected in South Africa on November 9, 2021, and is currently the only variant of concern ( 7 – 10 ).…”

Section: Introductionmentioning

confidence: 99%

“…The original Wuhan strain rapidly evolved into different variants, including Alpha (B.1.1.7 and Q lineages), Beta (7)(8)(9). The Omicron variant of 2019-nCoV was first detected in South Africa on November 9, 2021, and is currently the only variant of concern (7)(8)(9)(10).…”

Section: Introductionmentioning

confidence: 99%

Effect of nasal irrigation in adults infected with Omicron variant of COVID-19: A quasi-experimental study

Liu

Xie

et al. 2023

Front. Public Health

View full text Add to dashboard Cite

ObjectiveTo investigate the effect of nasal irrigation on the duration of symptoms and nucleic acid conversion in adults infected with the Omicron variant of COVID-19.MethodsThis quasi-experimental study enrolled patients diagnosed with asymptomatic, mild, or moderate Omicron infection at the Shandong Public Health Clinical Center between April 1, 2022 and May 1, 2022. Patients were divided into two groups to receive Lianhua Qingwen granules and traditional Chinese medicine (TCM) prescriptions (conventional group) and 3% hypertonic saline nasal irrigation based on conventional treatment (nasal irrigation groups), respectively. Primary outcomes were symptom disappearance time and nucleic acid negative conversion time. Secondary outcomes were peripheral blood white blood cell (WBC), lymphocyte (LYM) count, neutrophil (NEU) count, C-reactive protein (CRP) level, and chest CT examination findings.ResultsEighty patients were included (40 patients/group). Multiple linear regression analysis showed that, after adjustment for comorbidities, smoking history, LYM count, and Ct values of N gene, the patients in the nasal irrigation group were more likely to get lower nucleic acid negative conversion time (β = −11.052, 95% CI: −8.277–13.827, P < 0.001) compared with the conventional group. The symptom disappearance time showed no significant improvement (P > 0.05). Subgroup analysis for treatment-naïve patients in the nasal irrigation group showed similar nucleic acid negative conversion time improvement (P = 0.038).ConclusionEarly nasal irrigation shortens the nucleic acid negative conversion time in adults infected with the Omicron variant but without improvements in symptom disappearance time.

show abstract

“…The size of the peptides matters however, longer peptides tend to have lower IC 50 values. Larue et al (2020) reported that a 6 amino acid ACE2 fragment with a mM order IC 50 is able to reduce cell infection by approximately 70% (Larue et al, 2020), while Chatterjee et al (2020) reported 23 amino-acid peptides able to reduce the infection rate by 60% (Chatterjee et al, 2020), Kuznetsov et al (2022) reported that a 19 amino acid peptide has an IC close to μM (Kuznetsov et al, 2022), and Karoyan et al (2021) described a 27 amino acid with IC 50 on the order of nM (Karoyan et al, 2021). The miniproteins designed by Cao et al (2020) have much longer sizes, with over 55 amino acids for the best ones (Cao et al, 2020).…”

Section: Discussionmentioning

confidence: 99%

“…Their results show a difference in the folding mechanisms of the modified peptides (a two-state folding mechanism) binding the RBD, as opposed to the naturally occurring α1 helix peptides, suggesting that amino acid substitution on the alpha-helical sequences can result in subtle changes in dynamic properties compared to the wild-type sequence. Moreover, Kuznetsov et al (2022) have observed experimentally that a peptide comprising positions 24 to 42 of the ACE2 α1 helix can inhibit the formation of the S1-ACE2 complex in a manner dependent on the peptide concentration (Kuznetsov et al 2022). They also observed the formation of a ternary complex suggesting that the peptide could bind to other sites besides that observed in the structure of the complex.…”

Section: Preventing Virus Internalization By Inhibiting the Spike-ang...mentioning

confidence: 97%

Peptide-Based Strategies Against SARS-CoV-2 Attack: An Updated In Silico Perspective

Moroy

Tufféry

2022

Front. Drug. Discov.

View full text Add to dashboard Cite

Because of its scale and suddenness, the SARS-CoV-2 pandemic has created an unprecedented challenge in terms of drug development. Apart from being natural candidates for vaccine design, peptides are a class of compounds well suited to target protein-protein interactions, and peptide drug development benefits from the progress of in silico protocols that have emerged within the last decade. Here, we review the different strategies that have been considered for the development of peptide drugs against SARS-CoV-2. Thanks to progress in experimental structure determination, structural information has rapidly become available for most of the proteins encoded by the virus, easing in silico analyses to develop drugs or vaccines. The repurposing of antiviral/antibacterial peptide drugs has not been successful so far. The most promising results, but not the only ones, have been obtained targeting the interaction between SARS-CoV-2 spike protein and the Angiotensin-Converting Enzyme 2, which triggers cellular infection by the virus and its replication. Within months, structure-based peptide design has identified competing for picomolar candidates for the interaction, proving that the development of peptide drugs targeting protein-protein interactions is maturing. Although no drug specifically designed against SARS-CoV-2 has yet reached the market, lessons from peptide drug development against SARS-CoV-2 suggest that peptide development is now a plausible alternative to small compounds.

show abstract

ACE2 Peptide Fragment Interaction with Different S1 Protein Sites

Cited by 7 publications

References 21 publications

Inhibition of SARS-CoV-2 pathogenesis by potent peptides designed by the mutation of ACE2 binding region

Inhibition of SARS-CoV-2 pathogenesis by potent peptides designed by the mutation of ACE2 binding region

Effect of nasal irrigation in adults infected with Omicron variant of COVID-19: A quasi-experimental study

Peptide-Based Strategies Against SARS-CoV-2 Attack: An Updated In Silico Perspective

Contact Info

Product

Resources

About